Intervention

Ipilimumab

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 145 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials145

Recruiting12

Common conditions25

Lead sponsors shown15

Clinical trials

60 shown

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung CancerNCT07355205 · 2026-07-07

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast CancerNCT06324240 · 2025-12-02

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLCNCT06364917 · 2025-05-30

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyNCT06362369 · 2024-08-23

NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 TrialNCT06342037 · 2024-06-12

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379 · 2023-11-01

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung CancerNCT05501665 · 2023-05-09

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483 · 2021-12-14

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and NivolumabNCT04933903 · 2021-10-05

Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IONCT03815890 · 2019-10-04

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVONCT03816345 · 2019-07-16

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNCT03866382 · 2019-05-13

Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)NCT07770100 · 2026-10-01

NOT_YET_RECRUITING

A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)NCT06946797 · 2025-09-19

ACTIVE_NOT_RECRUITING

Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate CancerNCT06388369 · 2025-08-25

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaNCT06097728 · 2023-11-09

ACTIVE_NOT_RECRUITING

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With ImmunotherapyNCT05715229 · 2023-09-29

Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLCNCT05401786 · 2023-01-03

ACTIVE_NOT_RECRUITING

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 NegativeNCT04929041 · 2022-10-07

ACTIVE_NOT_RECRUITING

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung CancerNCT05005273 · 2022-10-03

EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPCNCT05150236 · 2022-04-29

A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLCNCT05144529 · 2022-03-22

A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese ParticipantsNCT05136677 · 2022-01-25

Study of Nivolumab-Ipilimumab and cfDNA in Lung CancerNCT04966676 · 2022-01-24

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal MesotheliomaNCT05041062 · 2021-12-01

Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain MetastasesNCT05012254 · 2021-11-18

ACTIVE_NOT_RECRUITING

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaNCT04940299 · 2021-09-23

ACTIVE_NOT_RECRUITING

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate CancerNCT04709276 · 2021-06-07

ACTIVE_NOT_RECRUITING

A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.NCT04855929 · 2021-05-25

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2NCT06790303 · 2021-03-04

Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate CancerNCT04717154 · 2021-01-19

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLCNCT04610658 · 2020-11-23

Neoadjuvant Immunotherapy in Brain MetastasesNCT04434560 · 2020-11-04

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyNCT04591431 · 2020-10-07

A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has SpreadNCT04132817 · 2020-09-22

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell CancersNCT04388852 · 2020-08-20

ACTIVE_NOT_RECRUITING

Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLCNCT04141644 · 2020-08-20

ACTIVE_NOT_RECRUITING

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine TumorsNCT04079712 · 2020-08-06

ACTIVE_NOT_RECRUITING

Microbiome Immunotherapy Toxicity and Response EvaluationNCT04107168 · 2020-07-08

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialNCT03878524 · 2020-04-01

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid TumorsNCT03993379 · 2019-11-20

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast CancerNCT03546686 · 2019-11-12

ACTIVE_NOT_RECRUITING

Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung CancerNCT04013542 · 2019-09-13

ACTIVE_NOT_RECRUITING

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver CancersNCT04021043 · 2019-08-19

Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLCNCT04043195 · 2019-08-14

ACTIVE_NOT_RECRUITING

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deletedNCT04185311 · 2019-07-10

Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual DiseaseNCT03818685 · 2019-07-02

Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial CancerNCT03989362 · 2019-06-06

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsNCT03645928 · 2019-05-07

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing CancerNCT03907852 · 2019-04-15

ACTIVE_NOT_RECRUITING

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer PatientsNCT03650894 · 2019-04-03

ACTIVE_NOT_RECRUITING

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast CancerNCT03789110 · 2019-03-08

ACTIVE_NOT_RECRUITING

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)NCT03739710 · 2019-01-24

Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland CancersNCT03749460 · 2019-01-15

Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)NCT03591731 · 2019-01-02

Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate CancerNCT03477864 · 2018-12-24

Immunotherapy in Patients With Metastatic Cancers and CDK12 MutationsNCT03570619 · 2018-12-14

Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLCNCT03573947 · 2018-10-02

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate CancerNCT03532217 · 2018-09-14

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung CancerNCT03575793 · 2018-09-06

Common conditions

Leading sponsors

Bristol-Myers Squibb24 M.D. Anderson Cancer Center14 National Cancer Institute (NCI)10 H. Lee Moffitt Cancer Center and Research Institute4 Memorial Sloan Kettering Cancer Center4 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins4 Dana-Farber Cancer Institute3 Merck Sharp & Dohme LLC3 The Netherlands Cancer Institute3 GlaxoSmithKline2 Incyte Biosciences International Sàrl2 Intergroupe Francophone de Cancerologie Thoracique2 Lawrence Fong2 NYU Langone Health2 SWOG Cancer Research Network2

Trial status mix

COMPLETED66

ACTIVE_NOT_RECRUITING28

TERMINATED28

RECRUITING12

UNKNOWN6

WITHDRAWN4

NOT_YET_RECRUITING1

Phase mix

PHASE295

PHASE153

PHASE319

EARLY_PHASE11

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.